Blue Trust Inc. Grows Stock Holdings in Organon & Co. (NYSE:OGN)

Blue Trust Inc. lifted its position in Organon & Co. (NYSE:OGN) by 217.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,661 shares of the company’s stock after purchasing an additional 2,508 shares during the quarter. Blue Trust Inc.’s holdings in Organon & Co. were worth $76,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Trust Co. of Vermont increased its position in shares of Organon & Co. by 109.4% during the third quarter. Trust Co. of Vermont now owns 2,626 shares of the company’s stock valued at $50,000 after acquiring an additional 1,372 shares during the last quarter. nVerses Capital LLC purchased a new position in Organon & Co. in the third quarter valued at $260,000. SeaCrest Wealth Management LLC increased its holdings in shares of Organon & Co. by 32.7% in the 3rd quarter. SeaCrest Wealth Management LLC now owns 16,218 shares of the company’s stock valued at $310,000 after acquiring an additional 3,999 shares during the last quarter. Sound Income Strategies LLC boosted its holdings in shares of Organon & Co. by 6.8% in the 3rd quarter. Sound Income Strategies LLC now owns 611,380 shares of the company’s stock valued at $11,696,000 after buying an additional 39,173 shares in the last quarter. Finally, Douglas Lane & Associates LLC boosted its stake in Organon & Co. by 0.7% in the third quarter. Douglas Lane & Associates LLC now owns 531,680 shares of the company’s stock valued at $10,171,000 after acquiring an additional 3,792 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on OGN shares. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. lowered Organon & Co. from a “neutral” rating to an “underweight” rating and upped their price objective for the stock from $18.00 to $20.00 in a report on Friday, September 6th.

Organon & Co. Trading Up 0.4 %

NYSE:OGN opened at $17.92 on Thursday. The company has a quick ratio of 1.17, a current ratio of 1.64 and a debt-to-equity ratio of 60.05. The company has a market capitalization of $4.61 billion, a PE ratio of 4.61, a price-to-earnings-growth ratio of 0.77 and a beta of 0.84. The stock has a fifty day simple moving average of $19.51 and a 200-day simple moving average of $20.10. Organon & Co. has a 52-week low of $10.84 and a 52-week high of $23.10.

Organon & Co. (NYSE:OGN) last announced its earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.04. The firm had revenue of $1.61 billion during the quarter, compared to the consensus estimate of $1.61 billion. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. The firm’s revenue for the quarter was down .1% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.31 EPS. On average, equities research analysts expect that Organon & Co. will post 4.04 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Shareholders of record on Friday, August 16th were paid a dividend of $0.28 per share. The ex-dividend date was Friday, August 16th. This represents a $1.12 annualized dividend and a yield of 6.25%. Organon & Co.’s dividend payout ratio is currently 28.79%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.